心血管

订阅

MedSci主页 / 所有栏目 / 心血管

Circulation：口服抗凝药暂停后 不宜用桥接抗凝？

2014-12-18 高晓方 译 医学论坛网

口服抗凝药桥接抗凝
关注

美国一项研究表明，暂时中断口服抗凝药(OAC)治疗的患者约有1/4接受桥接(Bridging)抗凝治疗，并且桥接抗凝治疗与出血和不良事件风险升高相关。论文12月12日在线发表于《循环》(Circulation)。 此项前瞻性观察研究为ORBIT-AF，共纳入7372例接受OAC治疗的房颤患者，并记录了因手术而暂时中断OAC治疗的情况，其中包括桥接抗凝治疗的应用和类型。转归指标包括30天内心梗、卒

美国一项研究表明，暂时中断口服抗凝药(OAC)治疗的患者约有1/4接受桥接(Bridging)抗凝治疗，并且桥接抗凝治疗与出血和不良事件风险升高相关。论文12月12日在线发表于《循环》(Circulation)。

此项前瞻性观察研究为ORBIT-AF，共纳入7372例接受OAC治疗的房颤患者，并记录了因手术而暂时中断OAC治疗的情况，其中包括桥接抗凝治疗的应用和类型。转归指标包括30天内心梗、卒中或系统栓塞、大出血、病因特异性住院和死亡发生率。中位随访时间为2年。

 结果显示，在随访期间至2年的2200例(30%)患者中，共发生2803起OAC中断事件，其中665例(24%)应用桥接抗凝治疗，主要为低分子量肝素和普通肝素。桥接治疗者更有可能既往有脑血管事件和机械瓣膜置换，但在CHA2DS2-VASc评分方面无显著差异。

过渡治疗者的出血事件较非过渡治疗者更为常见(P<0.0001)，30天内心梗、卒中或系统栓塞、大出血、住院和死亡发生率亦显著升高(13%对6.3%，校正OR值为1.94，P=0.0001)。

原始出处

Steinberg BA1, Peterson ED2, Kim S3, Thomas L3, Gersh BJ4, Fonarow GC5, Kowey PR6, Mahaffey KW7, Sherwood MW2, Chang P8, Piccini JP2, Ansell J9; on behalf of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients.Use and Outcomes Associated with Bridging During Anticoagulation Interruptions in Patients with Atrial Fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).Circulation. 2014 Dec 12.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1991931, encodeId=2049199193169, content=<a href='/topic/show?id=36ba6238527' target=_blank style='color:#2F92EE;'>#桥接抗凝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62385, encryptionId=36ba6238527, topicName=桥接抗凝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Tue Jun 30 18:07:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13341, encodeId=135c13341fd, content=桥接抗凝有风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc1609458, createdName=2012GMxl, createdTime=Mon Dec 22 22:26:00 CST 2014, time=2014-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377356, encodeId=b85a13e735668, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Sat Dec 20 01:07:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13256, encodeId=519d132563f, content=暂时中断口服抗凝药(OAC)治疗的患者约有1/4接受桥接(Bridging)抗凝治疗，并且桥接抗凝治疗与出血和不良事件风险升高相关。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=870092288, createdName=rosa00tong, createdTime=Fri Dec 19 06:36:00 CST 2014, time=2014-12-19, status=1, ipAttribution=)]
    2015-06-30 马龙

    #桥接抗凝#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1991931, encodeId=2049199193169, content=<a href='/topic/show?id=36ba6238527' target=_blank style='color:#2F92EE;'>#桥接抗凝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62385, encryptionId=36ba6238527, topicName=桥接抗凝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Tue Jun 30 18:07:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13341, encodeId=135c13341fd, content=桥接抗凝有风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc1609458, createdName=2012GMxl, createdTime=Mon Dec 22 22:26:00 CST 2014, time=2014-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377356, encodeId=b85a13e735668, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Sat Dec 20 01:07:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13256, encodeId=519d132563f, content=暂时中断口服抗凝药(OAC)治疗的患者约有1/4接受桥接(Bridging)抗凝治疗，并且桥接抗凝治疗与出血和不良事件风险升高相关。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=870092288, createdName=rosa00tong, createdTime=Fri Dec 19 06:36:00 CST 2014, time=2014-12-19, status=1, ipAttribution=)]
    2014-12-22 2012GMxl

    桥接抗凝有风险

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1991931, encodeId=2049199193169, content=<a href='/topic/show?id=36ba6238527' target=_blank style='color:#2F92EE;'>#桥接抗凝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62385, encryptionId=36ba6238527, topicName=桥接抗凝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Tue Jun 30 18:07:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13341, encodeId=135c13341fd, content=桥接抗凝有风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc1609458, createdName=2012GMxl, createdTime=Mon Dec 22 22:26:00 CST 2014, time=2014-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377356, encodeId=b85a13e735668, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Sat Dec 20 01:07:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13256, encodeId=519d132563f, content=暂时中断口服抗凝药(OAC)治疗的患者约有1/4接受桥接(Bridging)抗凝治疗，并且桥接抗凝治疗与出血和不良事件风险升高相关。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=870092288, createdName=rosa00tong, createdTime=Fri Dec 19 06:36:00 CST 2014, time=2014-12-19, status=1, ipAttribution=)]
    2014-12-20 hunizi005

    #口服抗凝药#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1991931, encodeId=2049199193169, content=<a href='/topic/show?id=36ba6238527' target=_blank style='color:#2F92EE;'>#桥接抗凝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62385, encryptionId=36ba6238527, topicName=桥接抗凝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Tue Jun 30 18:07:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13341, encodeId=135c13341fd, content=桥接抗凝有风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc1609458, createdName=2012GMxl, createdTime=Mon Dec 22 22:26:00 CST 2014, time=2014-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377356, encodeId=b85a13e735668, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Sat Dec 20 01:07:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13256, encodeId=519d132563f, content=暂时中断口服抗凝药(OAC)治疗的患者约有1/4接受桥接(Bridging)抗凝治疗，并且桥接抗凝治疗与出血和不良事件风险升高相关。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=870092288, createdName=rosa00tong, createdTime=Fri Dec 19 06:36:00 CST 2014, time=2014-12-19, status=1, ipAttribution=)]
    2014-12-19 rosa00tong

    暂时中断口服抗凝药(OAC)治疗的患者约有1/4接受桥接(Bridging)抗凝治疗，并且桥接抗凝治疗与出血和不良事件风险升高相关。

    0

相关资讯

新型口服抗凝药在房颤和ACS中将上位

　　欧洲心脏病学会（ESC）血栓工作组的一篇综述表明，新型口服抗凝药在诸多房颤患者中可取代维生素K拮抗剂，并且在急性冠脉综合征后有应用价值。论文发表于《美国心脏病学会杂志》[J Am Coll Cardiol 2012, 59:1413]。 　　直到不久前，维生素K拮抗剂仍是唯一可用的口服抗凝药，但其存在的诸多限制促使人们引入新型口服抗凝药。新型

Gastroenterology：新口服抗凝药增加消化道出血风险

新一代的口服抗凝药包括凝血酶和Xa因子的抑制剂，均显示较好的抗凝效果。但是不明确这些药物是否会增加患者消化道出血的风险。 需要频繁服用口服抗凝药的患者会有一些显著的合并症，并且可能会服用阿司匹林和/或噻吩并吡啶。 来自荷兰的Lisanne Holster医生对于服用抗凝药的患者发生消化道出血的风险及临床相关的出血进行了一项系统性综述和荟萃分析。[Gastroenterol&n

武剑：新型口服抗凝药时代，从循证证据到指南

房颤卒中二级预防策略探讨 首都医科大学宣武医院 武剑 随着近年来房颤卒中预防领域大量循证证据累积(尤其是新型口服抗凝药高质量大规模研究的发布)，各国相关指南都进行了很多重量级更新，但均聚焦于房颤卒中一级预防策略。自2014年始，美国两大神经科学会相继在房颤卒中二级预防领域更新了相关指南，美国神经病学学会(AAN)2月发布了《非瓣膜性心房颤动(NVAF)患者卒中

Am J Cardiol：PCI房颤患者，口服抗凝路漫漫

一项日本研究显示，真实世界中行PCI的房颤患者口服抗凝使用不足且抗凝强度往往不够，接受口服抗凝的患者长期使用双联抗血小板治疗(DAPT)未降低卒中发生率。论文4月25日在线发表于《美国心脏病学杂志》。 在CREDO-Kyoto登记队列-2中，研究者从12716例接受首次经皮冠脉介入术(PCI)的患者中识别出1057例房颤患者。尽管大多数(75.2%)房颤患者CHADS2评分≥2，但是仅5

Eur Heart J： 房颤射频消融术后长期使用口服抗凝药有无必要？

射频消融术是对症状性房颤药物治疗无效情况下的推荐治疗方法，然而目前仍不能确定射频消融术和房颤相关的血栓栓塞并发症的降低有关联。欧洲心脏病学会（ESC）指南在对于房颤的管理上从2010年就推荐房颤患者在射频消融术后应持续系统性地口服抗凝药（OAC）治疗至少3个月，而是否持久性口服抗凝治疗应基于病人个体的脑卒中危险因素水平来决定（Ⅱa级推荐， C 级证据），显而易见，对于脑卒中高风险患者即使射频消融后